JP2017531433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531433A5 JP2017531433A5 JP2017518884A JP2017518884A JP2017531433A5 JP 2017531433 A5 JP2017531433 A5 JP 2017531433A5 JP 2017518884 A JP2017518884 A JP 2017518884A JP 2017518884 A JP2017518884 A JP 2017518884A JP 2017531433 A5 JP2017531433 A5 JP 2017531433A5
- Authority
- JP
- Japan
- Prior art keywords
- del
- mutation
- ins
- patient
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000035772 mutation Effects 0.000 claims 18
- 102100010782 EGFR Human genes 0.000 claims 6
- 101700039191 EGFR Proteins 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 5
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 5
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 3
- 108010022830 Cetuximab Proteins 0.000 claims 2
- 238000001712 DNA sequencing Methods 0.000 claims 2
- 206010071975 EGFR gene mutation Diseases 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960001433 Erlotinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 229920000272 Oligonucleotide Polymers 0.000 claims 2
- 108010061219 Panitumumab Proteins 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 229940121647 EGFR inhibitors Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Claims (10)
- 上皮細胞増殖因子受容体(EGFR)遺伝子に変異を伴う細胞を抱える可能性のある腫瘍を有する患者を同定する方法であって、配列番号1における変異2257−2277>GCC、又は変異2257−2262 del、又は変異2266−2277 delにより特徴付けられる、変異されたEGFR遺伝子の存在について患者の試料を試験することを含み;これにより、該患者の試料中の変異の存在は、該患者が、EGFR阻害剤化合物に対し感受性があることを示す、方法。
- 前記EGFR阻害剤化合物が、セツキシマブ、パニツムマブ、エルロチニブ又はゲフィチニブである、請求項1記載の方法。
- 変異G719A、G719C、K745−A750 del K ins、E746V、E746K、L747S、E749Q、A750P、A755V、S768I、L858P、L858R、E746−R748 del、E746−S752 del V ins、L747− E749 del、L747−A750 del P ins、L747−T751 del、L747−T751 del P ins、L747−P753 del S ins、L747−S752 del、R748−P753 del、T751−I759 del T ins、S752−I759 del、P753− K757 del、M766−A767 del AI ins、S768−V769 del SVA ins、G779S、P848L、G857V、L858R、L861Q、L883S、D896Y、2236_2248>ACCC、2237_2244>CGCCC、2252_2277>AC、2240−2264>CGAAAGA、2239_2240 TT>CC、2264 C>A及びE746−A750 del AP insの1又は複数により特徴付けられる、変異されたEGFR遺伝子の存在について、患者の試料を試験すること;並びに、
もし1又は複数の変異が存在するならば、チロシンキナーゼ阻害剤による治療が成功する見込みがあることを決定すること、
を更に含む、請求項1又は2記載の方法。 - チロシンキナーゼ阻害剤療法に対する癌患者の反応の尤度を決定する方法であって、
(a)患者の試料中の、EGFR遺伝子の変異2257−2277>GCC、又は変異2257−2262 del、又は変異2266−2277 delに関して、患者の試料を試験すること、並びに、もし変異が存在するならば、
(b)患者が、チロシンキナーゼ阻害剤療法に対し反応する見込みがあることを決定すること、
を含む、方法。 - 前記チロシンキナーゼ阻害剤療法が、セツキシマブ、パニツムマブ、エルロチニブ又はゲフィチニブを含む、請求項4記載の方法。
- (a)EGFR遺伝子の変異G719A、G719C、K745−A750 del
K ins、E746V、E746K、L747S、E749Q、A750P、A755V、S768I、L858P、L858R、E746−R748 del、E746−S752 del V ins、L747−E749 del、L747−A750 del P ins、L747−T751 del、L747−T751 del P ins、L747−P753 del S ins、L747−S752 del、R748−P753 del、T751−I759 del T ins、S752−I759 del、P753−K757 del、M766−A767 del AI ins、S768−V769 del SVA ins、G779S、P848L、G857V、L858R、L861Q、L883S、D896Y、2236_2248>ACCC、2237_2244>CGCCC、2252_2277>AC、2240−2264>CGAAAGA、2239_2240 TT>CC、2264 C>A及びE746−A750 del AP insの1又は複数について、患者の試料を更に試験する工程;並びに
(b)もし変異のいずれかが存在すると報告されたならば、患者は、チロシンキナーゼ阻害剤療法に対し反応する見込みがあるであろうと決定する工程、
を更に含む、請求項4又は5記載の方法。 - 前記1又は複数の変異が、アレル特異的検出法によるか又はDNAシークエンシングにより検出される、請求項1〜6のいずれか一項記載の方法。
- 変異−特異的オリゴヌクレオチドにより、ヒトEGFR遺伝子の変異2257−2277>GCC、又は変異2257−2262 del、又は変異2266−2277 delを検出する方法。
- 前記オリゴヌクレオチドが、増幅プライマー又は検出プローブである、請求項8記載の方法。
- 前記1又は複数の変異が、アレル特異的検出法によるか又はDNAシークエンシングにより検出される、請求項8記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462061965P | 2014-10-09 | 2014-10-09 | |
US62/061,965 | 2014-10-09 | ||
PCT/EP2015/072844 WO2016055380A1 (en) | 2014-10-09 | 2015-10-02 | Mutations in the epidermal growth factor receptor kinase domain |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017531433A JP2017531433A (ja) | 2017-10-26 |
JP2017531433A5 true JP2017531433A5 (ja) | 2018-10-11 |
JP6694429B2 JP6694429B2 (ja) | 2020-05-13 |
Family
ID=54260746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017518884A Active JP6694429B2 (ja) | 2014-10-09 | 2015-10-02 | 上皮細胞増殖因子受容体キナーゼドメインにおける変異 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9994914B2 (ja) |
EP (1) | EP3204510B1 (ja) |
JP (1) | JP6694429B2 (ja) |
CN (1) | CN106795567B (ja) |
CA (1) | CA2961437C (ja) |
ES (1) | ES2688840T3 (ja) |
WO (1) | WO2016055380A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109722476A (zh) * | 2017-10-31 | 2019-05-07 | 北京雅康博生物科技有限公司 | 用于检测egfr基因2237-2257位突变的引物、探针及试剂盒 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4234086A1 (de) | 1992-02-05 | 1993-08-12 | Diagen Inst Molekularbio | Verfahren zur bestimmung von in vitro amplifizierten nukleinsaeuresequenzen |
US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
EP1733056B1 (en) | 2004-03-31 | 2013-05-22 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
WO2005118876A2 (en) | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Egfr mutations |
GB0506670D0 (en) | 2005-04-01 | 2005-05-11 | Astrazeneca Ab | Method |
GB2424886A (en) | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
EP1931798A1 (en) * | 2005-10-05 | 2008-06-18 | AstraZeneca UK Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
CN1884580B (zh) * | 2006-05-25 | 2011-12-07 | 邵建永 | 检测表皮生长因子受体基因位点突变的荧光定量pcr试剂盒 |
CN101092644B (zh) * | 2006-06-21 | 2010-07-14 | 上海基康生物技术有限公司 | 非小细胞肺癌疗效相关的egfr基因突变的快速检测 |
WO2008066498A1 (en) | 2006-12-01 | 2008-06-05 | Agency For Science, Technology And Research | Cancer-related protein kinases |
US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
CA2701726A1 (en) | 2007-10-04 | 2009-04-09 | Halcyon Molecular | Sequencing nucleic acid polymers with electron microscopy |
CN105200097A (zh) | 2008-10-20 | 2015-12-30 | 霍夫曼-拉罗奇有限公司 | 改进的等位基因特异性扩增 |
US20100143901A1 (en) | 2008-12-09 | 2010-06-10 | Roche Molecular Systems, Inc. | Nuclease-Free Real-Time Detection of Nucleic Acids |
US20120164641A1 (en) * | 2010-12-22 | 2012-06-28 | Roche Molecular Systems, Inc. | Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene |
US9738935B2 (en) | 2011-11-10 | 2017-08-22 | Roche Molecular Systems, Inc. | Complex mutations in the epidermal growth factor receptor kinase domain |
US20140341884A1 (en) | 2012-12-04 | 2014-11-20 | Roche Molecular Systems, Inc. | Novel Complex Mutations in the Epidermal Growth Factor Receptor Kinase Domain |
ES2662598T3 (es) | 2013-03-08 | 2018-04-09 | F. Hoffmann-La Roche Ag | Análisis de sangre para la detección de mutaciones de EGFR |
-
2015
- 2015-10-02 CN CN201580054582.4A patent/CN106795567B/zh active Active
- 2015-10-02 ES ES15775679.2T patent/ES2688840T3/es active Active
- 2015-10-02 WO PCT/EP2015/072844 patent/WO2016055380A1/en active Application Filing
- 2015-10-02 US US14/873,931 patent/US9994914B2/en active Active
- 2015-10-02 CA CA2961437A patent/CA2961437C/en active Active
- 2015-10-02 JP JP2017518884A patent/JP6694429B2/ja active Active
- 2015-10-02 EP EP15775679.2A patent/EP3204510B1/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11085086B2 (en) | Gene mutations and copy number alterations of EGFR, KRAS and MET | |
Mohan et al. | Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC | |
JP6709541B2 (ja) | 大腸癌に対する薬物療法の感受性を予測する方法 | |
US20170198353A1 (en) | Kras mutations and resistance to anti-egfr treatment | |
US20150139946A1 (en) | Detecting mutations in disease over time | |
JP2011505145A5 (ja) | ||
JP2011527575A5 (ja) | ||
WO2017094805A1 (ja) | ctDNA量の測定による悪性新生物に対する治療の効果を評価する方法 | |
JP2017531433A5 (ja) | ||
Büttner et al. | Intratumoral morphological heterogeneity can be an indicator of genetic heterogeneity in colorectal cancer | |
TWI449791B (zh) | 預測egfr突變肺腺癌病患對藥物治療的反應與預後之方法 | |
Qin et al. | Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer | |
JP2012524537A5 (ja) | ||
KR20210148077A (ko) | 면역 체크포인트 억제 요법으로부터의 수혜를 예측하는 방법 | |
ES2576084T3 (es) | Métodos de clasificación de muestras biológicas para predecir la respuesta al tratamiento con inhibidor de tirosina quinasa | |
Mondal et al. | EP16. 02-006 Evaluation of Carcinoembryonic Antigen (CEA) as Predictive Marker in Patients with Metastatic Non-small Cell Lung Cancer | |
Masykura et al. | P3. 01-053 Detection of Common EGFR Mutation in Cytological Smears Using Reversed Dot Blot (RDB) Hybridization Method | |
Lin et al. | EP16. 03-018 Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma | |
Durgut et al. | Droplet Digital PCR as a Molecular Tool for the Detection of the T790M Mutation in NSCLC Patients with the Activating Mutations | |
Garcia et al. | Next Generation Sequencing in Liquid Biopsies: Towards Personalized Cancer Treatment. | |
Ridwanuloh et al. | P3. 01-054 Urinary ct-DNA Testing of EGFR Common Mutation in Non-Small Cell Lung Cancer Patients | |
CN109722477A (zh) | 用于检测egfr基因2236-2252位突变的引物、探针及试剂盒 | |
Einert et al. | P1. 01 Identification of Prognostic Factors Using Image Analysis of HER2 Expression by Immunohistochemistry in Adenocarcinoma of the Oesophagogastric Junction | |
Lou et al. | JCES01. 21 Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection | |
CN109722469A (zh) | 用于检测egfr基因2319-2320位突变的引物、探针及试剂盒 |